African scientists call for more control of their continent’s genomic data
By Linda Nordling,
Science
| 04. 18. 2018
As the genomics revolution finally turns its attention to Africa and northern researchers flock there to collect data, scientists from the continent are demanding a larger role in projects.
On 18 April, a group of Africa-based researchers issued guidelines for the ethical handling of samples for genomic studies. The voluntary rules are an effort to combat ‘helicopter’ research, in which foreign scientists take samples and data from communities and then return to their home institutions. The guidelines also aim to ensure that African citizens see health benefits from research.
In recent years, researchers have begun sequencing the genomes of Africans in large numbers. The data offer insights into humanity’s past as well as predisposition to disease and potential reactions to drugs in African populations — the world’s most genetically diverse.
But because few institutions on the continent have the equipment to handle large genomic data sets, African scientists wanting to work on such projects have often had to accept terms offered by foreign partners, says Jantina de Vries, a bioethicist at the University of Cape Town in South...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...